Market Intelligence, Clinical Progress, and High-Purity Reagents for CNS and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NKCC1/SLC12A2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NKCC1/SLC12A2 Extracellular Loop Recombinant Protein. Sequence Verified. High Purity (>95%). Endotoxin Controlled. HEK293 Expressed. | View SLC12A2 Products |
| Full-Length Expression | SLC12A2 (NKCC1) Lentivirus Particles. HEK293 Expressed, Full ORF with native glycosylation, Endotoxin <1EU/ug. Sequence Verified. | View SLC12A2 Products |
| Gene Delivery | NKCC1/SLC12A2 Promise-ORF Lentivirus. Full-length ORF for stable cell line generation. Preserves native glycosylation and membrane topology. | View SLC12A2 Products |
| Benchmark Ab / Control | Anti-NKCC1/SLC12A2 Recombinant Antibody. Targeting extracellular loop 5. Sequence Verified. High purity (>95%), Endotoxin <1EU/ug. | View SLC12A2 Products |
| Validator | NKCC1/SLC12A2 siRNA Set (3 unique sequences). For knockdown verification and assay specificity controls. | View SLC12A2 Products |
| Related Target A (NKCC2) | SLC12A1 (NKCC2) Lentivirus Particles. Kidney-specific isoform for selectivity counter-screening. Sequence verified by mass spectrometry. | View SLC12A1 Products |
| Related Target B (KCC2) | SLC12A5 (KCC2) Lentivirus. Neuronal K-Cl cotransporter with antagonistic function to NKCC1. Synergistic pathway for epilepsy and pain. | View SLC12A5 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multipass membrane topology (12 TMs) | Lentivirus-encoded full-length protein in native membrane context; preserves conformational epitopes lost in purified systems. |
| Isoform selectivity (NKCC1 vs NKCC2) | Human SLC12A1 ortholog cell lines and lentivirus available for parallel selectivity profiling; sequence identity mapping provided. |
| Cross-species translation (human/cyno/mouse) | Human, Cynomolgus, and Mouse ortholog ORF clones and lentiviruses available; sequence verified for preclinical pharmacology. |
| Functional validation & false positives | Validated siRNA included for target engagement confirmation; reduces off-target effects. |
| Neuronal cell assay compatibility | Endotoxin <1EU/ug; HEK293 production ensures mammalian glycosylation patterns compatible with neuronal binding studies. |
Live NKCC1/SLC12A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (NKCC1)
- ➤ Latest Inhibitor Research (NKCC1)
- ➤ Recent Patent Filings (SLC12A2)
Global Clinical Landscape & Future Outlook
The race for NKCC1/SLC12A2 therapeutics is intensifying, with major efforts shifting from non-selective loop diuretic repurposing (e.g., bumetanide) toward isoform-selective CNS modulators and oncology biologics. First-generation bumetanide trials in autism and epilepsy face challenges with blood–brain barrier (BBB) penetration and kidney isoform (NKCC2) cross-reactivity, causing diuretic side effects. The next wave of R&D targets selective NKCC1 inhibition for epilepsy, autism spectrum disorder (ASD), traumatic brain injury (TBI), and glioblastoma cell volume regulation without triggering NKCC2-mediated diuresis. Next-generation biologics exploit extracellular epitopes on the 12-transmembrane structure for antibody-mediated inhibition, ADC strategies, and gene therapy approaches. Rigorous cell-based assays that preserve the transporter's multi-pass membrane topology are essential for accurate functional and selectivity profiling.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs:
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Iktos, Astellas, Sanofi, Otsuka, Various Academics | Epilepsy, Autism, Brain Edema | Isoform selectivity assay (need SLC12A2 vs SLC12A1 stable cell lines via lentivirus) |
| Prodrugs | Neurochlore, Servier | CNS Disorders, Schizophrenia | Functional cell-based assays (need high-titer lentivirus for robust transporter expression) |
| Inhibitory mAbs | Emerging Biotech (Sanofi collaboration) | Glioblastoma | Cell surface binding (need full-length lentivirus cell lines preserving native conformation) |
| ADC | Oncology Biotechs | Solid Tumors (ion flux drives metastasis) | Internalization assay (need high-expression stable cell lines) |
| siRNA / Gene Therapy | Academic Consortia, Early Biotech | Genetic Epilepsy, Glioma, Chronic Pain | Knockdown validation and expression validation (need benchmark Abs and specific siRNA sets) |